TY - JOUR T1 - Neoadjuvant Strategy as Initial Treatment in Resectable Pancreatic Cancer: Concrete Evidence of Benefit JF - Anticancer Research JO - Anticancer Res SP - 4673 LP - 4676 VL - 34 IS - 9 AU - FRANCESCA DE FELICE AU - DANIELA MUSIO AU - NICOLA RAFFETTO AU - VINCENZO TOMBOLINI Y1 - 2014/09/01 UR - http://ar.iiarjournals.org/content/34/9/4673.abstract N2 - Pancreatoduodenectomy remains the recommended treatment in potentially curative strategies for pancreatic carcinoma. Due to high local failure rates even after complete resection, a multi-modality treatment approach is paramount in the management of resectable disease. Despite there being insufficient evidence to recommend a specific neoadjuvant strategy, several studies have tested the use of preoperative chemoradiotherapy in this sub-group of patients, achieving promising results. The treatment is well-tolerated, with higher rates of negative margins and lower rates of lymph node positivity at resection, a decrease in local failure and benefit in overall survival. Considering the poor oncological results after primary surgical treatment, neoadjuvant strategy should be considered as a valid alternative in resectable pancreatic carcinoma. ER -